Back to Search Start Over

hERG1 and CA IX expression are associated with disease recurrence in surgically resected clear cell renal carcinoma.

Authors :
Lastraioli E
Pillozzi S
Mari A
Tellini R
Duranti C
Baldazzi V
Venturini S
Minervini A
Lapini A
Nesi G
Carini M
Arcangeli A
Source :
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2020 Jan; Vol. 46 (1), pp. 209-215. Date of Electronic Publication: 2019 Oct 31.
Publication Year :
2020

Abstract

Background: In search of novel prognostic biomarkers for clear cell renal carcinoma (ccRCC), we analysed the expression of several proteins related to angiogenesis and hypoxia.<br />Methods: A monocentric study on 30 consecutive surgical samples from surgically-treated ccRCC patients with a 10-year follow up was performed. The following proteins were analysed by immunohistochemistry: Vascular Endothelial Growth Factor- A (VEGF-A), Platelet-Derived Growth Factor β Receptor (PDGFRβ), VEGF-receptor 1 (Flt1), VEGF-receptor 2 (KDR), Glucose Transporter 1 (GLUT1), Carbonic anhydrase IX (CA-IX) and the hERG1 potassium channel. Data were analysed in conjunction with the clinico-pathological characteristics of the patients and follow up.<br />Results: All the proteins were expressed in the samples, with statistically significant associations of VEGF-A with PDGFRβ and Flt1 and hERG1 with CA IX. Notably, hERG1 and CAIX co-immunoprecipitated in primary ccRCC samples and survival analysis showed that the positivity for hERG1 and CA IX had a negative impact on Recurrence Free Survival (RFS) at the univariate analysis. At the multivariate analysis only hERG1 maintained its statistically significant negative impact.<br />Conclusions: hERG1 expression can be exploited to predict recurrence in surgically-treated ccRCC patients. hERG1 channels form a multiprotein complex with the pH regulator CA IX in primary ccRCC samples their potential use as therapeutic target might be suggested.<br /> (Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)

Details

Language :
English
ISSN :
1532-2157
Volume :
46
Issue :
1
Database :
MEDLINE
Journal :
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Publication Type :
Academic Journal
Accession number :
31679954
Full Text :
https://doi.org/10.1016/j.ejso.2019.10.031